General proliferating tumor and normal cells

General proliferating tumor and normal cells refers to a physiological state of active cell division rather than a specific molecular target like a receptor or enzyme (National Cancer Institute, 2023). This state is characterized by the progression through the cell cycle—G1, S, G2, and M phases—and is the primary target of traditional cytotoxic chemotherapy (American Cancer Society, 2024). These drugs, including antimetabolites, alkylating agents, and microtubule inhibitors, preferentially kill cells with high mitotic rates, such as malignant cells (PubMed, PMID: 25435214). However, because these agents do not distinguish between cancerous and healthy proliferating cells, they cause significant toxicity in tissues with high turnover, such as the bone marrow, intestinal epithelium, and hair follicles (StatPearls, NBK554440). Modern oncology has largely shifted toward molecularly targeted therapies to improve specificity and reduce the systemic side effects associated with targeting general cell proliferation (NIH, 2022).

Other names

Proliferating cellsMitotic cellsRapidly dividing cellsCycling cells

Cytotoxic chemotherapy agents target proliferating cells through various mechanisms: antimetabolites inhibit DNA synthesis during the S phase; alkylating agents cross-link DNA; and microtubule inhibitors disrupt the mitotic spindle during the M phase (National Cancer Institute, 2023).